As expected from previous reports, the cohort of t-MN selected for this study presented high rate of cytogenetic abnormalities, in particular del(5), del(7) and complex karyotype, and characteristic genetic signatures, with low incidence of mutations commonly detected in de-novo AML, such as NPM1 and FLT3, and higher incidence of TP53, NRAS and KRAS mutations [4]. The gene discussed is KRAS; the disease is acute myeloid leukemia.